NCCN PREFERRED FIRST-LINE THERAPY3‡

According to the National Comprehensive Cancer Network® (NCCN®), first-line amivantamab-vmjw (RYBREVANT®) + lazertinib (LAZCLUZE®) is the only NCCN Category 1 preferred multitargeted treatment option for patients with EGFR+§ mNSCLC.||¶

Unique multitargeted MOA

Discover how RYBREVANT FASPRO™ + LAZCLUZE® works

Explore more

RYBREVANT FASPRO™ dosing

Learn how to administer RYBREVANT FASPRO™

See how

Resources for you and your practice

Support your patients throughout their treatment journey

Learn more

‡EGFR mutation discovered prior to first-line systemic therapy.3

§EGFR exon 19 deletion or exon 21 L858R mutations.3

||See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other treatment options.

Prophylactic anticoagulation is recommended at the time of initiation to prevent venous thromboembolic events.3

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; mNSCLC, metastatic non–small cell lung cancer; MOA, mechanism of action; mOS, median overall survival; NE, not estimable; NSCLC, non–small cell lung cancer; OS, overall survival; PFS, progression-free survival.

References:

  1. RYBREVANT FASPRO™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Yang JC-H, Lu S, Hayashi H, et al; for the MARIPOSA Investigators. Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693. doi:10.1056/NEJMoa2503001
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 2, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.